Phase I Study of the Novel Investigational NEDD8-activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/refractory Multiple Myeloma or Lymphoma

PURPOSE: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma. EXPERIMENTAL DESIGN:...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Shah, Jatin J., Jakubowiak, Andrzej J., O’Connor, Owen A., Orlowski, Robert Z., Harvey, R. Donald, Smith, Mitchell R., Lebovic, Daniel, Diefenbach, Catherine, Kelly, Kevin, Hua, Zhaowei, Berger, Allison J., Mulligan, George, Faessel, Helene, Tirrell, Stephen, Dezube, Bruce J., Lonial, Sagar
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5694347/
https://ncbi.nlm.nih.gov/pubmed/26561559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1237
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller